Your browser doesn't support javascript.
Thrombosis risk assessment in patients with congenital thrombophilia during COVID - 19 infection.
Kovac, Mirjana; Mitic, Gorana; Milenkovic, Marija; Basaric, Dusica; Tomic, Branko; Markovic, Olivera; Zdravkovic, Marija; Ignjatovic, Vera.
  • Kovac M; Faculty of Medicine, University of Belgrade, Serbia; Blood Transfusion Institute of Serbia, Hemostasis Department, Belgrade, Serbia. Electronic address: mkovac008@gmail.com.
  • Mitic G; Faculty of Medicine Novi Sad, University of Novi Sad, Serbia.
  • Milenkovic M; Faculty of Medicine, University of Belgrade, Serbia; University Clinical Centre of Serbia, Belgrade, Serbia.
  • Basaric D; Blood Transfusion Institute of Serbia, Hemostasis Department, Belgrade, Serbia.
  • Tomic B; Institute of Molecular Genetics and Genetic Engineering, University of Belgrade, Belgrade, Serbia.
  • Markovic O; Faculty of Medicine, University of Belgrade, Serbia; University Clinical Hospital Center Bezanijska Kosa, Belgrade, Serbia.
  • Zdravkovic M; Faculty of Medicine, University of Belgrade, Serbia; University Clinical Hospital Center Bezanijska Kosa, Belgrade, Serbia.
  • Ignjatovic V; Murdoch Children's Research Institute, Parkville, Australia; Department of Paediatrics, The University of Melbourne, Australia.
Thromb Res ; 218: 151-156, 2022 10.
Article in English | MEDLINE | ID: covidwho-1996587
ABSTRACT

BACKGROUND:

Coagulation dysfunction represents a serious complication in patients during the COVID-19 infection, while fulminant thrombotic complications emerge as critical issues in individuals with severe COVID-19. In addition to a severe clinical presentation, comorbidities and age significantly contribute to the development of thrombotic complications in this disease. However, there is very little data on association of congenital thrombophilia and thrombotic events in the setting of COVID-19. Our study aimed to evaluate the risk of COVID-19 associated thrombosis in patients with congenital thrombophilia.

METHODS:

This prospective, case-control study included patients with confirmed COVID-19 infection, followed 6 months post-confirmation. The final outcome was a symptomatic thrombotic event. In total, 90 COVID-19 patients, 30 with known congenital thrombophilia and 60 patients without thrombophilia within the period July 2020-November 2021, were included in the study. Evaluation of hemostatic parameters including FVIII activity and D-dimer was performed for all patients at 1 month, 3 months and 6 months post-COVID-19 diagnosis.

RESULTS:

Symptomatic thrombotic events were observed in 7 out of 30 (23 %) COVID-19 patients with thrombophilia, and 12 out of 60 (20 %) without thrombophilia, P = 0.715. In addition, the two patient groups had comparable localization of thrombotic events, time to thrombotic event, effect of antithrombotic treatment and changes in FVIII activity, while D-dimer level were significantly increased in patients without thrombophilia.

CONCLUSION:

Our findings suggest that patients with congenital thrombophilia, irrespective of their age, a mild clinical picture and absence of comorbidities, should receive anticoagulant prophylaxis, adjusted based on the specific genetic defect.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Thrombosis / Hemostatics / Thrombophilia / COVID-19 Type of study: Cohort study / Diagnostic study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid Limits: Humans Language: English Journal: Thromb Res Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Thrombosis / Hemostatics / Thrombophilia / COVID-19 Type of study: Cohort study / Diagnostic study / Experimental Studies / Observational study / Prognostic study / Randomized controlled trials Topics: Long Covid Limits: Humans Language: English Journal: Thromb Res Year: 2022 Document Type: Article